Brief: IMAC Announces Opening Enrollment In Its Phase 1 Clinical Study Of Umbilical Cord-Derived Mesenchymal Stem Cells
05/11/2020 14:15
Nov 5 (Reuters) - IMAC Holdings Inc IMAC.O :
* IMAC HOLDINGS, INC. ANNOUNCES OPENING ENROLLMENT IN ITS
PHASE 1
CLINICAL STUDY OF UMBILICAL CORD-DERIVED MESENCHYMAL STEM CELLS
FOR THE TREATMENT OF BRADYKINESIA DUE TO PARKINSON’S DISEASE
Source text for Eikon: ID:nGNX7sZBQQ
Further company coverage: IMAC.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Imac Holdings
See all newsBrief: Nasdaq To Suspend Imac Holdings Stock Trading On March 26, 2025
Imac Holdings Inc Reports Results For The Quarter Ended September 30: Earnings Summary
Brief: Imac Holdings Inc - Regains Compliance With Nasdaq Audit Committee Rule
Imac Holdings Inc Reports Results For The Quarter Ended June 30: Earnings Summary
Brief: IMAC Holdings Enters Agreement To Issue 4,676 Shares Of Series G Preferred Stock